The Career Development Program is a critical component of the SPORE in Prostate Cancer, as it provides a mechanism to mentor junior investigators interested in careers in prostate cancer research. The Career Development Program (CDP) uses several mechanisms to recruit these investigators including emails, letters to department chairs and web site announcements. In addition, the Directors of the Robert H. Lurie Comprehensive Cancer Center and the University of Chicago Comprehensive Cancer Center will advertise the CDP when recruiting junior investigators to their respective Institutions. CDP investigators are selected after careful review of their credentials, their proposed projects and their potential to develop an independent career in prostate cancer research. Career Development investigators are clinicians or basic scientists from biomedical science departments at Northwestern University, University of Chicago and NorthShore University HealthSystem. The fact that the awardees come from a variety of departments provides a source of diversity and scientific expertise to members of the SPORE Program. The Career Development Program has a consistent and highly structured process for selection of awardees and a good tracking system for monitoring their progress.
The specific aims of the Career Development Program are:
Specific Aim 1 To recruit and solicit applications for career development investigators through a highly structured process including mechanisms to attract women and minority candidates.
Specific Aim 2 To select, monitor and evaluate career development investigators based on the proposed project, progress reports, publications and attendance at seminars and symposia.
Specific Aim 3 To foster the careers of these junior investigators through a structured program of mentor meetings, conferences, seminars and symposia.
CAREER DEVELOPMENT PROGRAM: PROJECT NARRATIVE The Career Development Program is a critical component of the SPORE in Prostate Cancer, in that it ensures that there will be a continuous influx of talented investigators devoted to prostate cancer research.
|Anker, Jonathan F; Mok, Hanlin; Naseem, Anum F et al. (2018) A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer. J Vis Exp :|
|Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999|
|Pascal, Laura E; Wang, Yao; Zhong, Mingming et al. (2018) EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer. Neoplasia 20:351-363|
|Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504|
|Anker, Jonathan F; Naseem, Anum F; Mok, Hanlin et al. (2018) Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 9:1591|
|Zang, Yachen; Pascal, Laura E; Zhou, Yibin et al. (2018) ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells. Cancer Lett 415:198-207|
|Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680|
|Catalona, William J (2018) Prostate Cancer Screening. Med Clin North Am 102:199-214|
|Zhang, Qiang; Helfand, Brian T; Carneiro, Benedito A et al. (2018) Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-? Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. Eur Urol 73:648-652|
|Szmulewitz, Russell Z; Peer, Cody J; Ibraheem, Abiola et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 36:1389-1395|
Showing the most recent 10 out of 67 publications